[Prospects for the use of fullerenes as antioxidants in pathogenetic therapy of bronchial asthma].
Bronchial asthma (BA) is a commonest respirative pathology; severe BA not infrequently has a fatal outcome. Oxidative stress is an important pathogenetic component of BA. Hyperactivity of lipid peroxidation may be due to primary genetically determined functional insufficiency of the anti-oxidative system. Recent progress in medical nanothechnologies, e.g. the use of BA fullerenes (C60) with anti-oxidative properties, opens up the possibility to obtain hydrated C60 producing no acute or chronic toxic effects and use them as therapeutic and preventive drugs for enteral and parenteral administration to humans with BA.
Shirinkin
S V
SV
Chyrnosov
M I
MI
Andrievskiĭ
G V
GV
Vasil'chenko
L V
LV
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D001249:Asthma / Q000097:blood / Q000188:drug therapy*; D002264:Carboxylic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D037741:Fullerenes / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D015227:Lipid Peroxidation / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects; D016896:Treatment Outcome
D000975:Antioxidants; C416673:C60 carboxyfullerene; D002264:Carboxylic Acids; D037741:Fullerenes